Collagen type 1 β-carboxy-telopeptide

1. Canagliflozin increases collagen type 1 β-carboxy-telopeptide in humans.

   “At week 52, canagliflozin was associated with an increase in collagen type 1 β-carboxy-telopeptide that was significantly correlated with a reduction in body weight”

   Human trialtype 2 diabetes mellitusbone52 weeks

   Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

   The Journal of clinical endocrinology and metabolism·18 Nov 2015

More on Canagliflozin